Lindbrook Capital, LLC Aldeyra Therapeutics, Inc. Transaction History

Lindbrook Capital, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	SELL	$1.47 - $6.06 $343 - $1,418	-234 Reduced 30.08%	544 $1,000
Q2 2023 Jul 28, 2023	BUY	$7.11 - $11.89 $2,964 - $4,958	417 Added 115.51%	778 $6,000
Q1 2023 Apr 26, 2023	SELL	$5.77 - $9.93 $871 - $1,499	-151 Reduced 29.49%	361 $3,000
Q4 2022 Jan 24, 2023	SELL	$5.08 - $7.09 $1,264 - $1,765	-249 Reduced 32.72%	512 $0
Q1 2022 Apr 21, 2022	SELL	$3.25 - $5.17 $5,785 - $9,202	-1,780 Reduced 70.05%	761 $3,000
Q4 2021 Jan 18, 2022	BUY	$3.5 - $9.63 $8,893 - $24,469	2,541 New	2,541 $10,000
Q4 2019 Jan 27, 2020	SELL	$4.73 - $7.98 $14,190 - $23,940	-3,000 Closed	0 $0
Q2 2019 Jul 24, 2019	BUY	$6.0 - $9.0 $18,000 - $27,000	3,000 New	3,000 $18,000

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $279M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.